Abstract
During 2022-2023, the Antimicrobial Resistance Laboratory Network tested 8,033 Candida auris clinical isolates in the United States. Overall, 95% of isolates were fluconazole resistant, 15% amphotericin B resistant, and 1% echinocandin resistant. Laboratory capacity for C. auris identification and antifungal susceptibility testing is essential to address this emerging public health threat.
Cite
CITATION STYLE
Laury, J. E., Forsberg, K., Berkow, E. L., Jones, S., Joseph Sexton, D., Sievert, D. M., … Lyman, M. (2026, February 1). Candida auris Testing by the Antimicrobial Resistance Laboratory Network, United States, 2022–2023. Emerging Infectious Diseases. Centers for Disease Control and Prevention (CDC). https://doi.org/10.3201/eid3202.251043
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
